Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.32 |
| ▸ | CNR2 | P34972 | 5/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10249976 | 0.82 | MGAM (0.36) | ALDH1A1TDP1TRPA1 | |
| SCHEMBL2558809 | 0.80 | HMGCR (0.40) | CNR1CNR2ALDH1A1TDP1 | |
| SCHEMBL18414852 | 0.78 | MAOA (0.41) | CNR1CNR2 | |
| SCHEMBL19844616 | 0.75 | KDM4E (0.31) | ALDH1A1TDP1 | |
| SCHEMBL23730058 | 0.75 | PIK3CD (0.35) | PIK3CD | |
| SCHEMBL690784 | 0.74 | — | — | |
| SCHEMBL1817888 | 0.74 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL18902220 | 0.73 | — | — | |
| SCHEMBL23730266 | 0.73 | MCL1 (0.38) | CNR1CNR2PIK3CDTRPA1TRPV1 | |
| SCHEMBL22237181 | 0.73 | GAA (0.39) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144824-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2023-05-11 | — | — | US | disclosed |
| EP-3950685-A1 | PYRAZOLOPYRIDINE COMPOUND AS RET INHIBITOR AND APPLICATION THEREOF | Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory (CN) | 2022-02-09 | — | — | EP | disclosed |
| WO-2021154669-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144824-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | TLR7, TLR9, TLR1 | CNR1 860/4885CNR2 1161/4885ALDH1A1 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.